Merck & Co., Inc. (NYSE:MRK) Shares Sold by Argent Advisors Inc.

Argent Advisors Inc. decreased its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,588 shares of the company’s stock after selling 100 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.9% of Argent Advisors Inc.’s portfolio, making the stock its 27th largest holding. Argent Advisors Inc.’s holdings in Merck & Co., Inc. were worth $2,189,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Merck & Co., Inc. by 3.8% during the 4th quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock valued at $9,331,676,000 after buying an additional 3,153,333 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after buying an additional 4,731,152 shares in the last quarter. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $3,108,366,000. Royal Bank of Canada lifted its position in shares of Merck & Co., Inc. by 12.8% during the 4th quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock valued at $1,632,255,000 after buying an additional 1,696,151 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Merck & Co., Inc. by 1.7% during the 4th quarter. Fisher Asset Management LLC now owns 13,566,968 shares of the company’s stock valued at $1,479,071,000 after buying an additional 228,578 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.5 %

MRK stock opened at $126.45 on Monday. The company’s 50 day moving average price is $129.14 and its 200 day moving average price is $125.13. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $134.63. The firm has a market capitalization of $320.27 billion, a price-to-earnings ratio of 140.50, a PEG ratio of 2.44 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Analysts Set New Price Targets

Several research analysts have recently commented on MRK shares. Truist Financial lifted their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Wells Fargo & Company lifted their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Finally, Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Read Our Latest Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.